For many incurable human cancer types better prognostic markers and more effective treatments are required. The MMSET histone methyltransferase is frequently found translocated in multiple myelomas with poor prognosis. In this study we show that MMSET may play a much broader role in human cancer than previously anticipated. We demonstrate that MMSET is overexpressed in several types of human tumors, including carcinomas of the gastrointestinal tract and skin. Interestingly, in bladder cancer MMSET expression correlates with tumor aggressiveness. Taken together these results suggest that MMSET is a strong candidate target for the development of novel anti-cancer drugs and suggest that MMSET expression is a potential marker for tumor aggressiveness. Further validations of MMSET expression were carried out on independent, tumorspecific sets of TMAs for urinary bladder (n=1293) and colon cancer (n=1206) with corresponding clinico-pathological data and long-term follow-up.
Statement of Translational Relevance
For many incurable human cancer types better prognostic markers and more effective treatments are required. The MMSET histone methyltransferase is frequently found translocated in multiple myelomas with poor prognosis. In this study we show that MMSET may play a much broader role in human cancer than previously anticipated. We demonstrate that MMSET is overexpressed in several types of human tumors, including carcinomas of the gastrointestinal tract and skin. Interestingly, in bladder cancer MMSET expression correlates with tumor aggressiveness. Taken together these results suggest that MMSET is a strong candidate target for the development of novel anti-cancer drugs and suggest that MMSET expression is a potential marker for tumor aggressiveness. 
Introduction
MMSET/WHSC1/NSD2 is a SET domain containing histone lysine methyltransferase that can di-and trimethylate histone H3 at lysine 36 (H3K36) (1, 2) . However, other specificities for MMSET have also been reported (3) (4) (5) . The H3K36 methylation mark is present in transcriptionally active genes (6) presumably contributing to repression of inappropriate transcription inside transcribed genes (7, 8) . In addition to the SET domain, MMSET also contains other conserved domains including plant homeodomain (PHD) zinc fingers, a high mobility group box (HMG) domain, and proline-tryptophane rich (PWWP) domains (Fig 1A) , found in proteins with DNA and chromatin binding activities (9) (10) (11) (12) . The MMSET gene is located at chromosome 4p16.3 and undergoes alternative splicing (13) (14) (15) resulting in several protein isoforms: MMSET type I, MMSET type II, and RE-IIBP (Fig. 1A) . Northern blotting has revealed that MMSET mRNA is expressed in highly proliferating embryonic tissues while primarily in adult thymus and testis (3, 13) .
MMSET is also known as nuclear receptor SET domain (NSD)2 and belongs to a family of NSD proteins (1-3) (16) . These proteins are related to S. cerevisiae Set2 and they all posses H3K36 histone methyltransferase activity (1, 2, 17, 18) . Another name for MMSET is Wolf-Hirschhorn syndrome candidate 1 (WHSC1), because it maps to the Wolf-Hirschhorn syndrome (WHS) critical region at 4p16. 3 (14) . This region is invariably lost in all cases of WHS, a congenital syndrome characterized by several somatic defects and mental retardation. MMSET is involved in the reciprocal t(4;14)(p16;q32) translocation in a subgroup of multiple myeloma (15-20% of cases) that is associated with poor prognosis (13, (19) (20) (21) (22) . High expression of MMSET appears to be involved in myelomagenesis, as the t(4;14) translocation has been detected at a significantly lower frequency in patients with the benign condition, monoclonal gammopathy of undetermined significance (MGUS) (21, 23, 24) . Recent data have shown that MMSET expression is essential for growth of myeloma cell lines in tissue culture and in xenografts, indicating that MMSET contributes to tumor maintenance in vivo (4, 25, 26) . However, a direct contribution of aberrantly expressed MMSET to tumorigenesis remains to be shown. Recent studies have also described high levels of MMSET mRNA in hepatocellular carcinoma (27) In this study, we have addressed MMSET protein expression in multiple human tumor types. We found that MMSET expression is frequently detected in many different cancers in comparison to the corresponding normal tissues. Particular frequent and/or high MMSET protein expression was found in carcinomas of the gastrointestinal (GI) tract (esophagus, stomach, colon, anal canal), small cell lung carcinoma (SCLC), and tumors of the urinary bladder, female genitals, and skin. 
Materials and Methods

Tissue culture
Human osteosarcoma U2OS cells were cultured in a humidified incubator at 37°C with 5% CO 2 in Dulbecco's Modified Eagle Medium (DMEM; Gibco) with 10% FCS (Hyclone), 100 μg/ml penicillin (Gibco), and 100 μg/ml streptomycin (Gibco). 
Production of a MMSET monoclonal antibody and applicability on formalin-fixed cells.
Immunoblotting
Protein extracts for immunoblots were obtained using high-salt lysis buffer (50 mM Tris, pH 7.2, 300 mM NaCl, 0.5%, IGEPAL CA-630, 1 mM DTT, 1 mM EDTA, 1 μg/ml Leupeptin, 1 μg/ml Aprotinin and 1mM PMSF) and sonication (Branson Digital Sonifier, 3x 5 sec, 20%, 0°C). Immunoblotting was performed according to standard protocols.
Antibodies used: 9A6 mAb (1:4; hybridoma supernatant), β-TUBULIN (Santa Cruz, sc-9104, 1:10000)
Tissue microarrays and staining with MMSET antibody
MMSET protein expression was analyzed by comprehensive IHC screenings of tissue microarrays (TMA) containing a total of 3774 FFPE archival samples (diameter 0.6 mm) from many different human tumors and 904 corresponding controls from normal tissues (cohort 1) (29) . Further validation of MMSET expression patterns in colorectal adenocarcinomas and urinary bladder tumors was carried out on independent, tumorspecific sets of TMA (cohort 2: colorectal adenocarcinoma, n=1206; cohort 3: urinary bladder tumors, n=1293) (29) . Corresponding clinico-pathological data and long-term follow-up were available for all patients in cohort 2 and 3. All these archival samples (provided by RS and GS) were derived from tissues previously collected for routine diagnostic procedures performed at the Dept. of Pathology, University Medical Center Hamburg-Eppendorf, in accordance with the principles of the "Ethik-Kommission der The terms in brackets indicate that in the vast majority of the samples, a correlation was observed between the number of positive cells and the intensity of the nuclear staining. A minimum of 100 relevant cells was counted. As a reference value of score 2, the positive staining of germinal centers in lymph nodes with follicular hyperplasia was used.
Omission and substitution of 9A6 mAb with unspecific Ig was utilized as negative control. Uninformative TMA samples (fallen off during processing; poor quality due to artifact; not representative; fewer than 100 tumor cells in the sample) were excluded from the scores.
Biopsies from multiple myeloma patients
A series of 39 FFPE bone marrow biopsies from patients diagnosed with multiple myeloma (provided by ER, Dept. of Pathology, Rigshospitalet, University of Copenhagen) were immunostained with the 9A6 mAb. These archival samples were collected as part of the routine diagnostic procedures according to the guidelines of the Danish National Board of Health.
Statistics
All statistic analyses were performed using R. Fisher's exact test (for total counts >500, p-values were estimated using Monte Carlo simulations) and Kaplan-Meier log-rank test were used. A p<0.05 was considered significant. 
Results
Development of a MMSET specific monoclonal antibody
The GST-tagged antigen and the correspondingly generated MMSET mAb (9A6) are shown in Fig. 1A . The 9A6 mAb recognizes the protein isotypes MMSET type I and II (but not RE-IIBP) and the specificity of the antibody was demonstrated by immunoblotting (Fig. 1B) . U2OS cells were transduced either with a lentivirus expressing a shRNA knocking down MMSET I+II or with control virus for 48 hours and subsequently selected with puromycin for 48 hours. The cells were harvested, lysed, and resolved by SDS-PAGE followed by immunoblotting (Fig. 1B) Interestingly, high and/or frequent MMSET expression was detected in many different cancer types, in contrast to most of the corresponding normal tissues or most benign tumors that showed no MMSET expression (Table I) . Importantly, MMSET protein expression was primarily present in malignant tumors (Table I) . Consistent with this notion, mucoepidermoid carcinoma, the only malignant tumor of the salivary glands represented in the TMA, was also the only one to show some MMSET expression (12/39: 31%) in comparison to normal parotis tissue and benign salivary gland tumors, such as Whartin's tumor, pleomorphic adenoma, and basal cell adenoma (Table I) Table I ). In addition, high expression was observed in urinary bladder tumors (Table I) , and in a fraction of serous and endometroid carcinomas of ovary and corpus uteri as well as in cervix carcinomas ( Supplementary Fig. S2 ). Also, some skin tumors displayed MMSET expression ( Supplementary Fig. S3 ).
The majority of testicular seminomas and all non-seminomatous germ cell tumors were MMSET-negative, while 14/53 teratomas (26%) showed significant expression, though mostly confined to blastema-like component or primitive neuroepithelial structures present in immature teratomas (Table 1) . Few samples representing the various subtypes of breast carcinoma showed some, but mostly weak MMSET expression (Table 1) .
Mammary phylloides tumors were all negative, whereas significant expression was (Table I) .
Tumors of the gastrointestinal tract
Among the tumors of the GI tract, frequent MMSET expression was detected in squamous carcinomas (21/54: 39%) and adenocarcinomas (31/55: 56%) of the esophagus (Table 1) 
MMSET expression in colon tumors
MMSET expression was found to be high in colorectal adenocarcinomas and premalignant dysplasia (Fig. 4A, left) We found a significant difference in MMSET expression in the different stages of the tumor where pT1 differed significantly from pT3 and pT4 ( Fig. 4C, left The clinical data for the colorectal adenocarcinomas also included age, sex, tumor diameter, localization, and differentiation grade, presence vs. absence of peritumoral lymphocytes, presence vs. absence of vascular invasion. None of these features showed a significant correlation with MMSET expression (data not shown).
Based on these results, we suggest that MMSET expression could play an important role in progression into the early stages of colorectal carcinogenesis (dysplasia). However, 4 years after diagnosis, MMSET expression is an independent negative prognostic marker.
MMSET expression in bladder cancer
MMSET expression is also high in tumors of the urinary bladder (Fig. 5A, left) . No 
3), for which corresponding clinico-pathological data and long-term follow-up were available (Supplementary table III p=1.0x10 -6 ). In agreement with this finding, a positive correlation was also found between MMSET expression and the stage of the tumor (Fig. 5C , upper right; Fisher's exact test, pTa vs. pT1, p=1.0x10 -6 ; pTa vs. pT2-pT4, p=1.0x10 -6 ). The same trend was observed for cohort 1 (Fig. 5A) . Furthermore, age also correlated positively with MMSET expression (Fig. 5C 
correlated positively with progression to more aggressive tumor stages ( Fig. 5D ; log-rank test, p=6.3x10 -4 ).
The clinical data for the bladder cancer patients also included survival, sex, several samples from a patient over time, unicentric versus multicentric tumors, and smoking status. However, none of these parameters showed a statistically significant correlation with MMSET expression (data not shown).
Taken together, our results indicate that MMSET plays a role in development of aggressive urinary bladder cancer.
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on However, in our screening, we only detected a weak MMSET expression in 4/26 (15%) oligodendrogliomas and no MMSET expression was observed in astrocytomas (n=44) ranging from low-to high-grade (glioblastomas, Table I ). In multiple myeloma, we detected MMSET expression in 33% of samples that highly correlated with the presence of the t(4;14) translocation (present in 38%). Due to an MMSET intragenic translocation breakpoint in approximately 33% of the t(4;14)
+ myeloma cases (19, 23, 32, 33) , the 9A6 mAb (recognizing the N-terminal part of MMSET) is not able to detect overexpressed truncated MMSET in these myeloma cases. In line with this, we found 3/10 t(4;14)
+ myelomas where the 9A6 mAb did not detect the MMSET protein (Supplementary Table   I ). The detection of 38% t(4;14) + myelomas should be compared to the observation that the t(4;14) translocation and increased levels of MMSET mRNA are normally detected in 15-20% of multiple myelomas (21, 22) . The overrepresentation of the t(4;14) + subgroup could be due to the small number of myelomas, as they were randomly included in the MMSET protein isoforms including the N-terminal truncated ones (resulting from the t(4;14) translocation) should be used.
In agreement with our study, high MMSET mRNA levels have been observed in cancers from bladder, colon, esophagus, liver, lung, and ovary in comparison to normal control tissue (27, 28) . However, we also observed high MMSET protein levels in malignant tumors from salivary glands, stomach, cervix uteri, corpus uteri, and skin. These differences could be explained by the fact that the approaches were different and that mRNA and protein are not always comparable and can be regulated in different ways. In fact, our unpublished results suggest that MMSET is regulated at posttranslational levels during differentiation, and that increased MMSET protein levels therefore could be a result of the stability of the MMSET protein.
In urinary bladder cancer, MMSET protein was detected in 40% of the cases and was associated with aggressiveness: expression levels correlated with poor prognostic markers (stage, grade, age and type of tumor growth), and progression. In line with this, a correlation between the grade of the urinary bladder cancer and MMSET mRNA expression has also been described (28). Supplementary Fig. S1B ). a.a.: amino acids. I n fi l t r a t i n g n = 7 3 4
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